Gastric cancer

GC · Oncology · 5 drugs · 5 indications

Cancer of the stomach. Includes gastroesophageal junction (GEJ) tumors.

Competitive Landscape (5 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
volrustomig	AZN	PD-1 + TIGIT dual blockade	Bispecific	IV	PHASE3
Enhertu	AZN, DSNKY	HER2-directed (DXd payload)	ADC	IV	APPROVED
Herceptin	ROG.SW	HER2 antagonist	Antibody	IV/SC	APPROVED
Keytruda	MRK	PD-1 inhibitor	Antibody	IV	APPROVED
Vyloy	ALPMY	CLDN18.2-targeting	Antibody	IV	APPROVED

Indications (5)

CLDN18.2+ G/GEJ adenocarcinoma 1L

Vyloy APPROVED

HER2+ Gastric Cancer

Gastric/GEJ

Keytruda APPROVED

HER2-positive gastric cancer

Enhertu APPROVED

Gastric/GEJ cancer

Upcoming Catalysts

Enhertu + Pertuzumab - 1L HER2+ mBC - FDA Approval (DESTINY-Breast09)REGULATORY

DSNKYJan 23, 2026

Sac-TMT + Keytruda - 1L NSCLC - Ph3 - Update (OptiTROP-Lung05)CLINICAL

MRK2026

Enhertu - Global Sales TrajectoryCOMMERCIAL

DSNKY2026

Vyloy - Global Launch TrajectoryCOMMERCIAL

ALPMY2026

Keytruda - LOE PreparationCOMPETITIVE

MRKOngoing

Vyloy + Keytruda + Chemo - 1L Gastric - Ph3 - Updates (LUCERNA)CLINICAL

ALPMY2027+

Data from Supabase · Updated 2026-03-24